Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;38(4):311-318.
doi: 10.1089/jop.2021.0104. Epub 2022 Apr 18.

Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty

Corine Ghosn  1 , Lakshmi Rajagopalan  1 , Sveti Ugarte  1 , Shruti Mistry  1 , Werhner Orilla  1 , Margot L Goodkin  1 , Michael R Robinson  1 , Michael Engles  1 , Mohammed Dibas  1
Affiliations

Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty

Corine Ghosn et al. J Ocul Pharmacol Ther. 2022 May.

Abstract

Purpose: To assess the intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost implant following selective laser trabeculoplasty (SLT) in a canine model. Methods: Unilateral SLT was performed in 11 normotensive, treatment-naive beagle dogs. IOP was measured at baseline (pre-SLT) and weekly post-SLT (≤10 weeks). After IOP returned to baseline or at 10 weeks (whichever occurred first), a sustained-release bimatoprost implant was administered bilaterally in the anterior chamber of each animal. IOP was measured weekly for 4 weeks and then every 2 weeks up to week 42. Results: The main outcomes included the IOP change (%) from baseline, calculated in both eyes in the overall population, SLT responder subgroup (defined by peak IOP reduction from baseline ≥3 mmHg or ≥15% for >1 week post-SLT), and SLT nonresponder subgroup (defined by peak IOP reduction from baseline <3 mmHg or <15%). The bimatoprost implant lowered IOP similarly in both the SLT-treated and fellow SLT-naive eyes. Following bimatoprost implant administration, the mean (standard deviation [SD]) peak IOP reduction from baseline was 34.4% (8.5%) in SLT-treated eyes and 35.7% (5.9%) in fellow SLT-naive eyes. The bimatoprost implant lowered IOP comparably (P > 0.17) in eyes that responded to SLT (mean [SD] peak IOP reduction, 34.6% [10.7%]; n = 6) and those that did not (mean [SD] peak IOP reduction, 34.1% [6.1%]; n = 5). Conclusion: The bimatoprost implant effectively lowered IOP in eyes pretreated with SLT, regardless of response to SLT. The current data suggest that eyes previously treated with SLT can still benefit from the intracameral bimatoprost implant.

Keywords: bimatoprost; glaucoma; intraocular pressure; laser trabeculoplasty; ocular hypertension; sustained-release implant.

PubMed Disclaimer

Conflict of interest statement

Financial arrangements of the authors with companies whose products may be related to the present report follow, as declared by the authors. C.G., L.R., S.U., S.M., W.O., M.L.G., M.R.R., M.E., and M.D. are employees of AbbVie, Inc., and may hold AbbVie stock. Neither honoraria nor payments were made for authorship.

Figures

FIG. 1.
FIG. 1.
Selective laser trabeculoplasty involved 2 sessions during which the nasal or temporal area (180° each) of the trabecular meshwork (A) was treated with adjacent/nonoverlapping laser spots (B) to cover the entire 360°. DPZ, deep pigmented zone; I, iris; PLS, pectinate ligament strands; TM, light (bluish) pigmented zone of trabecular meshwork.
FIG. 2.
FIG. 2.
Mean percentage change in IOP from baseline in SLT responder and nonresponder eyes. Data are expressed as mean (SD). IOP, intraocular pressure; SD, standard deviation; SLT, selective laser trabeculoplasty.
FIG. 3.
FIG. 3.
Mean IOP in SLT-treated and fellow SLT-naive eyes of (A) SLT responders and (B) SLT nonresponders following administration of the bimatoprost implant. Data are expressed as mean (SD). BimSR, bimatoprost sustained-release; IOP, intraocular pressure; SD, standard deviation; SLT, selective laser trabeculoplasty.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Weinreb, R.N., Aung, T., and Medeiros, F.A.. The pathophysiology and treatment of glaucoma: a review. JAMA. 311:1901–1911, 2014. - PMC - PubMed
    1. American Academy of Ophthalmology. Preferred Practice Patterns—Primary open-angle glaucoma. 2020. https://www.aaojournal.org/article/S0161-6420(15)01276-2/pdf Accessed March 16, 2022. - PubMed
    1. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br. J. Ophthalmol. 105:1–169, 2021. - PubMed
    1. Craven, E.R., Walters, T., Christie, W.C., et al. . 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 80:167–179, 2020. - PMC - PubMed
    1. Seal, J.R., Robinson, M.R., Burke, J., et al. . Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J. Ocul. Pharmacol. Ther. 35:50–57, 2019. - PMC - PubMed

Publication types

LinkOut - more resources